Jeleń Filip

Founder & CEO @ Pure Biologics and Captor Therapeutics

Founder & CEO at Pure Biologics Inc. and Captor Therapeutics Inc. Serial entrepreneur with 15+ years of scientific and R&D managing experience, both in Poland and USA and over 8 years of experience in building start-ups. Received his PhD in biochemistry from the University of Wroclaw and executive MBA from the Polish-American Business School.
Trained at the Institute for Molecular Medicine in Houston Medical Center, USA in the lab of Nobel Prize laureate, prof. Murad. Currently leads the business and operational activities of two drug development companies, coordinating teams of 120 specialists and having over 220 million PLN under management for ultra innovative R&D projects.

Pure Biologics S.A.
Pure Biologics Inc. is a NewConnect listed biopharmaceutical company, the first in Poland that develops innovative biological drugs in the field of immuno-oncology, as well as medical devices for therapeutic use. Pure Biologics generates recurring revenues from contract research that include selection of active molecules (antibodies and aptamers), production and analysis of recombinant proteins. The company currently employs >65 (thereof 40% with a PhD) highly qualified specialists and operates in a modern 1,000 sqm laboratory (ISO 17025) in Wroclaw Technology Park, which allows the company to conduct and control all stages of R&D relating to biological drug development in-house.

Captor Therapeutics S.A.
Captor Therapeutics is a fast-growing biopharmaceutical company, globally one of few focused on the development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options. Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called “undruggable proteome”. Captor Therapeutics’ integrated competencies and expertise in biology and chemistry allow to perform all stages of early drug development.

Talks